Advisors Asset Management Inc. decreased its holdings in Danaher Corporation (NYSE:DHR) by 14.7% in the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 69,221 shares of the conglomerate’s stock after selling 11,908 shares during the quarter. Advisors Asset Management Inc.’s holdings in Danaher were worth $5,938,000 as of its most recent filing with the SEC.
Several other large investors have also added to or reduced their stakes in the company. Legal & General Group Plc boosted its stake in Danaher by 5.5% during the first quarter. Legal & General Group Plc now owns 2,902,919 shares of the conglomerate’s stock valued at $248,286,000 after buying an additional 150,368 shares in the last quarter. EULAV Asset Management boosted its stake in Danaher by 0.5% during the first quarter. EULAV Asset Management now owns 192,000 shares of the conglomerate’s stock valued at $16,422,000 after buying an additional 1,000 shares in the last quarter. Hartland & Co. LLC boosted its stake in Danaher by 8.3% during the first quarter. Hartland & Co. LLC now owns 11,849 shares of the conglomerate’s stock valued at $1,013,000 after buying an additional 910 shares in the last quarter. Rothschild Asset Management Inc. boosted its stake in Danaher by 15.0% during the first quarter. Rothschild Asset Management Inc. now owns 574,804 shares of the conglomerate’s stock valued at $49,163,000 after buying an additional 75,179 shares in the last quarter. Finally, Simmons Bank boosted its stake in Danaher by 0.7% during the first quarter. Simmons Bank now owns 7,134 shares of the conglomerate’s stock valued at $611,000 after buying an additional 53 shares in the last quarter. 75.56% of the stock is owned by institutional investors.
Shares of Danaher Corporation (NYSE DHR) opened at $94.02 on Monday. Danaher Corporation has a one year low of $76.27 and a one year high of $94.24. The company has a debt-to-equity ratio of 0.42, a quick ratio of 1.00 and a current ratio of 1.43. The firm has a market capitalization of $65,400.00, a PE ratio of 24.17, a PEG ratio of 2.24 and a beta of 1.02.
Danaher (NYSE:DHR) last posted its quarterly earnings results on Thursday, October 19th. The conglomerate reported $1.00 earnings per share for the quarter, topping the Zacks’ consensus estimate of $0.95 by $0.05. Danaher had a return on equity of 11.29% and a net margin of 13.36%. The company had revenue of $4.53 billion during the quarter, compared to the consensus estimate of $4.47 billion. During the same period last year, the business earned $0.87 EPS. The business’s quarterly revenue was up 9.6% on a year-over-year basis. equities research analysts anticipate that Danaher Corporation will post 3.99 earnings per share for the current fiscal year.
In other Danaher news, SVP Daniel Raskas sold 37,870 shares of the firm’s stock in a transaction that occurred on Thursday, November 16th. The stock was sold at an average price of $93.33, for a total value of $3,534,407.10. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CAO Robert S. Lutz sold 11,189 shares of the firm’s stock in a transaction that occurred on Monday, October 23rd. The stock was sold at an average price of $91.66, for a total value of $1,025,583.74. Following the completion of the sale, the chief accounting officer now owns 18,314 shares of the company’s stock, valued at approximately $1,678,661.24. The disclosure for this sale can be found here. In the last three months, insiders have sold 317,498 shares of company stock worth $28,838,801. 12.20% of the stock is currently owned by insiders.
Several equities research analysts have recently commented on DHR shares. Morgan Stanley upped their target price on Danaher from $95.00 to $98.00 and gave the company an “overweight” rating in a report on Friday, October 20th. Credit Suisse Group upped their target price on Danaher from $93.00 to $96.00 and gave the company an “outperform” rating in a report on Friday, October 20th. Zacks Investment Research raised Danaher from a “hold” rating to a “buy” rating and set a $97.00 target price for the company in a report on Thursday, October 5th. Goldman Sachs Group Inc reaffirmed a “neutral” rating and set a $83.00 target price on shares of Danaher in a report on Tuesday, September 26th. Finally, Robert W. Baird upped their target price on Danaher from $87.00 to $97.00 and gave the company an “outperform” rating in a report on Friday, October 20th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating, thirteen have assigned a buy rating and one has issued a strong buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $93.31.
Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.
Receive News & Ratings for Danaher Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher Corporation and related companies with MarketBeat.com's FREE daily email newsletter.